Relief Therapeutics and NeuroX to combine in new company
Biotechnology company Relief Therapeutics has announced a business combination with commercial-stage company NeuroX to create a new digital neurotherapeutics company.
The business combination follows approval from Relief’s shareholders, who have also approved a capital increase through the issuance of 140 million new ordinary shares.
The business combination is expected to close in December 2025, subject to remaining closing conditions, including the admission of the newly issued shares to trading on the SIX Swiss Exchange.
The new digital neurotherapeutics company will aim to combine Relief’s specialty biopharmaceutical portfolio with NeuroX’s brain health platform.
Upon completion of the business combination, Alexandre Capet is expected to serve as Chief Executive Officer and Frédéric Condolo as Chief Technology Officer. Both are part of the current leadership of NeuroX and joined MindMaze in 2023.
Bruno Quinney, Content Team, DDW
